Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GrayBug: Long view in AMD

GrayBug developing extended-release anti-angiogenic therapy for AMD

GrayBug LLC is looking to treat age-related macular degeneration by combining two technologies - a small molecule therapeutic and an extended-release polymer carrier - to achieve sustained inhibition of hypoxia-inducible factor 1 activity in the retina.

Hypoxia-inducible factor 1 (HIF1) is a transcription factor that upregulates VEGF and other angiogenic proteins in response to low oxygen levels.

GrayBug co-founder

Read the full 576 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE